

INTERNATIONAL KNOWLEDGE SHARING ON NEGOTIATIONS OF NEW AND EXPENSIVE PHARMACEUTICALS

On the 24th and 25th of October 2024, representatives from various pharmaceutical negotiation organizations convened in Lisbon, Portugal. The purpose of this meeting was to discuss current and future trends within medicines and share strategies for negotiating new, high-cost pharmaceuticals that often have limited evidence of effectiveness.

This gathering aimed to foster a comprehensive exchange of insights and experiences, with the goal of identifying best practices and potential solutions to ensure sustainable and equitable access to effective medicines. Discussions particularly focused on the challenges posed by the lack of evidence on the effectiveness of high-priced new medicines and the increasing pressure on pharmaceutical budgets.

Hence the participants also explored the advantages, disadvantages and experiences with alternative and performance-based pricing agreements without discussing confidential information.

The group also discussed the need for strengthening the future collaboration, especially within strategic horizon scanning.

Representatives from the following organizations were in attendance: INFARMED (Portugal), Amgros (Denmark), Dutch Ministry of Health (Netherlands), Vienna Healthcare Group (Austria), Norwegian Hospital Procurement Trust (Norway), RIZIV/INAMI/NIHDI (Belgium), Swedish Association of Local Authorities and Regions (Sweden).

This is the third meeting in the group since 2021.